23andMe Holding released three new genetic reports for 23andMe+ members on breast, colorectal and prostate cancer. The reports are based on statistical models known as polygenic risk scores, developed by 23andMe through its proprietary research database. These PRS reports calculate the likelihood of an individual developing one of these cancers, based on thousands of genetic variants associated with the disease. “Using these reports to understand your likelihood to develop common cancers is an important step toward further integrating genetics into healthcare,” said Noura Abul-Husn, Vice President of Genomic Health at 23andMe. “Today, there is increasing evidence and support for the use of PRS in personalized disease prevention, and certain medical specialties – including oncology – have already begun to adopt this to inform clinical decision-making. These new reports will help customers better understand their overall likelihood for developing these diseases, and enable them to work with their healthcare providers to implement prevention plans.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ME:
- 23andMe Launches New Genetic Reports on Common Forms of Cancer
- 23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
- 23andMe price target lowered to 85c from 90c at Citi
- 23andMe reduces FY24 revenue view to $215M-$220M, consensus $245.45M
- 23andMe Reports Third Quarter Fiscal 2024 Financial Results